Rapid Research Response to the 2019 Novel Coronavirus Outbreak: Development of Targeted Diagnostics, Therapeutics and Comparative Pathogenicity Assessment

对 2019 年新型冠状病毒爆发的快速研究响应：开发靶向诊断、治疗和比较致病性评估

• 批准号: 422580
• 负责人: Langlois Marc-Andre
• 金额: $ 72.85万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-02-01 至 2022-02-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=422580&lang=en
• 关键词: 2019-Ncov; Coronavirus; Covid-19; Diagnostics; Mers; Pathogenicity; Sars; Sars-Cov-2; Vaccine; Viral Evolution; 2019-Ncov; Coronavirus; Covid-19; Diagnostics; Mers; Pathogenicity; Sars; Sars-Cov-2; Vaccine; Viral Evolution

In 2019, the world has seen the emergence of a virus that causes pneumonia in humans, which has a high probability of resulting in complications that include acute respiratory distress syndrome and death in an estimated 0.2% to 5% of cases. Coronavirus di

在2019年，世界已经看到了引起人类肺炎的病毒的出现，该病毒的可能性很大，导致并发症，包括急性呼吸窘迫综合征和死亡，估计为0.2％至5％。冠状病毒DI